Search results
New Study Published on Specialty Enzymes & Probiotics' Powerhouse Probiotic SEBtilis™
Morningstar· 4 days agoCHINO, Calif., April 25, 2024 /PRNewswire/ -- A functional assessment of Bacillus subtilis PLSSC (SEBtilis™) demonstrated its antimicrobial activity and capability to offer ...
FDA Approves New Bladder Cancer Drug
Medscape· 7 days agoThe first-in-class agent is approved alongside bacillus Calmette-Guérin to treat certain non–muscle-invasive bladder cancers that do not respond to ...
These DIY all natural pesticides will keep bugs out of your house
KOAA5· 4 days agoLooking to move away from traditional repellents? All natural pesticides can act as substitutes for...
FDA OKs First IL-15 Receptor Agonist for Early Bladder Cancer
MedPage Today· 7 days agoThe FDA approved nogapendekin alfa inbakicept (Anktiva) for bacillus Calmette-Guérin...
Immunotherapy Combination Approved for Non-Muscle Invasive Bladder Cancer
Technology Networks· 6 days agoThe U.S. Food and Drug Administration (FDA) has approved the immunotherapy-boosting drug N-803,...
Why Is ImmunityBio Stock Trading Higher On Tuesday? - ImmunityBio (NASDAQ:IBRX)
Benzinga· 6 days agoMonday, the FDA approved ImmunityBio Inc’s IBRX Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for BCG-unresponsive non-muscle invasive ...
Scientists find microencapsulation technique boosts tea tree oil efficiency for sustainable...
Phys.org· 3 hours agoIn a study published in the Journal of Bioresources and Bioproducts, a team of scientists led by Peifu Kong has successfully prepared tea tree oil-beta-cyclodextrin (TTO-β-CD) microcapsules ...
enGene (NASDAQ:ENGN) Coverage Initiated by Analysts at Wells Fargo & Company
ETF DAILY NEWS· 7 days agoWells Fargo & Company assumed coverage on shares of enGene (NASDAQ:ENGN – Free Report) in a research report sent to investors on Monday morning, Marketbeat Ratings reports. The brokerage issued ...
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for...
Morningstar· 7 days agoImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Designated an FDA Breakthrough Therapy, the novel immunotherapy ANKTIVA activates the body’s natural killer
Bioinsecticides Market Projected to Reach USD 232.14 Million by 2031 Driven by Shift Towards...
Digital Journal· 10 hours agoThe SNS Insider report indicates that the Bioinsecticides Market size was USD 99.35 million in 2023...